Antiangiogenic agents in the management of non-small cell lung cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60:277 - 300; PMID: 20610543; http://dx.doi.org/10.3322/caac.20073
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932 - 936; PMID: 16355210; http://dx.doi.org/10.1038/nature04478
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006; 312:1171 - 1175; PMID: 16728631; http://dx.doi.org/10.1126/science.1125950
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 2009; 14:612 - 620; PMID: 19474164; http://dx.doi.org/10.1634/theoncologist.2008-0287
   PubMed Web of Science ®Google Scholar
• Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009; 9:507 - 517; PMID: 19344286; http://dx.doi.org/10.1517/14712590902817817
   PubMed Web of Science ®Google Scholar
• AVASTIN^® (bevacizumab) Solution for intravenous infusion [package insert] 2011; South San Francisco, CA Genentech, Inc.
   Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184 - 2191; PMID: 15169807; http://dx.doi.org/10.1200/JCO.2004.11.022
   PubMed Web of Science ®Google Scholar
• Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010; 79:27 - 38; PMID: 21051914; http://dx.doi.org/10.1159/000314980
   PubMed Web of Science ®Google Scholar
• Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16:269 - 278; PMID: 20028762; http://dx.doi.org/10.1158/1078-0432.CCR-09-2439
   PubMed Web of Science ®Google Scholar
• Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255 - 5261; PMID: 19738122; http://dx.doi.org/10.1200/JCO.2009.22.0616
   PubMed Web of Science ®Google Scholar
• Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11:733 - 740; PMID: 20650686; http://dx.doi.org/10.1016/S1470-2045(10)70151-0
   PubMed Web of Science ®Google Scholar
• Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 2011; 104:413 - 418; PMID: 21245868; http://dx.doi.org/10.1038/sj.bjc.6606074
   PubMed Web of Science ®Google Scholar
• Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, et al. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 2005; 118:3759 - 3768; PMID: 16105884; http://dx.doi.org/10.1242/jcs.02483
   PubMed Web of Science ®Google Scholar
• Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007; 117:2766 - 2777; PMID: 17909625; http://dx.doi.org/10.1172/JCI32479
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287 - 1295; PMID: 12727920; http://dx.doi.org/10.1172/JCI17929
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18:338 - 340; PMID: 14657001; http://dx.doi.org/10.1096/fj.030271fje
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542 - 2550; PMID: 17167137; http://dx.doi.org/10.1056/NEJMoa061884
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60 - 65; PMID: 18165641; http://dx.doi.org/10.1200/JCO.2007.13.1144
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009; 27:1227 - 1234; PMID: 19188680; http://dx.doi.org/10.1200/JCO.2007.14.5466
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21:1804 - 1809; PMID: 20150572; http://dx.doi.org/10.1093/annonc/mdq020
   PubMed Web of Science ®Google Scholar
• Leighl NB, Zatloukal P, Mezger J, Ramlau R, Moore N, Reck M, et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010; 5:1970 - 1976; PMID: 20978447; http://dx.doi.org/10.1097/JTO.0b013e3181f49c22
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284 - 3289; PMID: 19433684; http://dx.doi.org/10.1200/JCO.2008.20.8181
   PubMed Web of Science ®Google Scholar
• Miller VA, O'Conner P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27:8002
   Google Scholar
• Kabbinavar FF, Miller VA, Johnson BE, O'Connor PG, Soh C. TLAS I. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). [Abstract 7526]. J Clin Oncol 2010; 28
   Google Scholar
• Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced nonsmall-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377:1846 - 1854; PMID: 21621716; http://dx.doi.org/10.1016/S0140-6736(11)60545-X
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Garst J, Jahanzeb M, Kosty MP, Vidaver R, Beatty S, et al. Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). [Abstract 7618]. J Clin Oncol 2010; 28
   Google Scholar
• Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009; 10:252 - 256; PMID: 19632943; http://dx.doi.org/10.3816/CLC.2009.n.035
   PubMed Web of Science ®Google Scholar
• Dahlberg SE, Ramalingam SS, Belani CP, Schiller JH. A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). J Clin Oncol 2011; 29 [abstract TBS 218]
   Google Scholar
• Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 2010; 11:352 - 357; PMID: 20837462; http://dx.doi.org/10.3816/CLC.2010.n.045
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano S, Leighl NB, et al. Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer. J Thorac Oncol 2011; 6 [abstract 042.03]
   PubMedGoogle Scholar
• Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28:780 - 787; PMID: 20048182; http://dx.doi.org/10.1200/JCO.2009.23.7537
   PubMed Web of Science ®Google Scholar
• Camidge DR, Ballas MS, Dubey S, Haigentz M, Rosen PJ, Spicer JF, et al. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28 abstract 7588
   Google Scholar
• National Cancer Institute. NCI Drug Dictionary January 5, 2011 http://www.cancer.gov/drugdictionary/
   Google Scholar
• Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010; 5:1054 - 1059; PMID: 20593550; http://dx.doi.org/10.1097/JTO.0b013e3181e2f7fb
   PubMed Web of Science ®Google Scholar
• Novello S, Ramlau R, Gorbunova VA, Ciuleanu TE, Ozguroglu M, Goksel T, et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): Final results of a multinational placebo-controlled phase III trial (EFC10261-VITAL) 2011; Amsterdam, Netherlands Abstract associated with oral presentation at: the 14th Biennial World Conference on Lung Cancer; July 3–7, 2011 [abstract O43.06]
   Google Scholar
• Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2008; 3:128 - 130; PMID: 18520295; http://dx.doi.org/10.1097/JTO.0b013e318174e95a
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 2002; 62:4645 - 4655; PMID: 12183421
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009; 27:2523 - 2529; PMID: 19332730; http://dx.doi.org/10.1200/JCO.2008.18.6015
   PubMed Web of Science ®Google Scholar
• Lee J, Hirsh V, Park K, Qin S, Blajman CR, Perng R, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010; 28 [abstract 7525]
   Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11:619 - 626; PMID: 20570559; http://dx.doi.org/10.1016/S1470-2045(10)70132-7
   PubMed Web of Science ®Google Scholar
• de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29:1067 - 1074; PMID: 21282537; http://dx.doi.org/10.1200/JCO.2010.29.5717
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059 - 1066; PMID: 21282542; http://dx.doi.org/10.1200/JCO.2010.28.5981
   PubMed Web of Science ®Google Scholar
• AstraZeneca. AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC June 23, 2010 Available at: http://www.astrazeneca.com/media/latest-press-releases/zactima-adv-NSCLC?itemId=317146
   Google Scholar
• Aisner J, Manola J, Dakhil SR, Stella PJ, Schiller JH. Randomized phase II study of vandetanib (V), docetaxel (D) and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment, progression-free survival (PFS) and overall survival (OS). [Abstract 7560]. J Clin Oncol 2011; 29
   Google Scholar
• Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 2008; 3:131 - 134; PMID: 18520296; http://dx.doi.org/10.1097/JTO.0b013e318174e910
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65:4389 - 4400; PMID: 15899831; http://dx.doi.org/10.1158/0008-5472.CAN-04-4409
   PubMed Web of Science ®Google Scholar
• Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28:49 - 55; PMID: 19917841; http://dx.doi.org/10.1200/JCO.2009.22.9427
   PubMed Web of Science ®Google Scholar
• NCIC Clinical Trials Group. Site Committee Open/Closed/Planned/On Hold/Withdrawn Studies August 11, 2011 http://www.ctg.queensu.ca/public/Clinical_Trials/ph3_trial_accrual_closed.htm
   Google Scholar
• Gadgeel SM, Ruckdeschel JC, Wozniak AJ, Chen W, Hackstock D, Galasso C, et al. Cediranib, a VEGF receptor 1, 2 and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29 [abstract 7564]
   Google Scholar
• Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774 - 4782; PMID: 18559524; http://dx.doi.org/10.1158/0008-5472.CAN-07-6307
   PubMed Web of Science ®Google Scholar
• Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010; 16:2881 - 2889; PMID: 20460487; http://dx.doi.org/10.1158/1078-0432.CCR-09-2944
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Eschbach C, Stefanic M, Love J, Gatzemeier U, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; 22:1374 - 1381; PMID: 21212157; http://dx.doi.org/10.1093/annonc/mdq618
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099 - 7109; PMID: 15466206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
   PubMed Web of Science ®Google Scholar
• Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008; 26:26 - 31 [abstract 8014]
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced nonsmall-cell lung cancer. J Clin Oncol 2010; 28:1835 - 1842; PMID: 20212250; http://dx.doi.org/10.1200/JCO.2009.26.1321
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Eisen T, Santoro A, Paz-Ares L, Bennouna J, Liao M, et al. Sorafenib (S) + gemcitabine/cisplatin (GC) vs. GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): Phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Ann Oncol 2010; 21:viii
   Google Scholar
• Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2582 - 2589; PMID: 21576636; http://dx.doi.org/10.1200/JCO.2010.30.7678
   PubMed Web of Science ®Google Scholar
• Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. [Abstract 7513]. J Clin Oncol 2011; 29
   Google Scholar
• Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46:1116 - 1119; PMID: 12646019; http://dx.doi.org/10.1021/jm0204183
   PubMed Web of Science ®Google Scholar
• Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650 - 656; PMID: 18235126; http://dx.doi.org/10.1200/JCO.2007.13.9303
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti GV, Rosell R, Socinski MA, Brahmer J, Atkins J, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101:1543 - 1548; PMID: 19826424; http://dx.doi.org/10.1038/sj.bjc.6605346
   PubMed Web of Science ®Google Scholar
• Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010; 5:354 - 360; PMID: 20032789; http://dx.doi.org/10.1097/JTO.0b013e3181c7307e
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study. Ann Oncol 2010; 21:viii [abstract LBA6]
   Google Scholar
• Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008; 9:1324 - 1335; PMID: 19037839
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6:2012 - 2021; PMID: 17620431; http://dx.doi.org/10.1158/1535-7163.MCT-07-0193
   PubMed Web of Science ®Google Scholar
• Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol 2010; 28:3131 - 3137; PMID: 20516450; http://dx.doi.org/10.1200/JCO.2009.23.9749
   PubMed Web of Science ®Google Scholar
• Jonker DJ, Rosen LS, Sawyer M, Wilding G, Noberasco C, Jayson G, et al. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK) and pharmacodynamic (PD) findings. J Clin Oncol 2007; 25:25 - 31 [abstract 3559]
   PubMedGoogle Scholar
• Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146 - 6153; PMID: 18829493; http://dx.doi.org/10.1158/1078-0432.CCR-08-0509
   PubMed Web of Science ®Google Scholar
• Mekhail T, Masson E, Fischer BS, Gong J, Iyer R, Gan J, et al. Metabolism, excretion and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab Dispos 2010; 38:1962 - 1966; PMID: 20671097; http://dx.doi.org/10.1124/dmd.110.033951
   PubMed Web of Science ®Google Scholar
• Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, et al. Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006; 5:995 - 1006; PMID: 16648571; http://dx.doi.org/10.1158/1535-7163.MCT-05-0410
   PubMed Web of Science ®Google Scholar
• Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007; 109:3400 - 3408; PMID: 17209055; http://dx.doi.org/10.1182/blood-2006-06-029579
   PubMed Web of Science ®Google Scholar
• Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6:1418 - 1425; PMID: 21597387; http://dx.doi.org/10.1097/JTO.0b013e318220c93e
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474 - 5483; PMID: 16027439; http://dx.doi.org/10.1200/JCO.2005.04.192
   PubMed Web of Science ®Google Scholar
• Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27:3836 - 3841; PMID: 19597027; http://dx.doi.org/10.1200/JCO.2008.20.8355
   PubMed Web of Science ®Google Scholar
• Fujisaka Y, Yamada Y, Yamamoto N, Shimizu T, Fujiwara Y, Yamada K, et al. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2010; 66:935 - 943; PMID: 20107802; http://dx.doi.org/10.1007/s00280-010-1243-y
   PubMed Web of Science ®Google Scholar
• Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66:8715 - 8721; PMID: 16951187; http://dx.doi.org/10.1158/0008-5472.CAN-05-4665
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, et al. Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011; 22:2057 - 2067; PMID: 21321086; http://dx.doi.org/10.1093/annonc/mdq731
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Vynnychenko I, Ichinose Y, Park K, Kubota K, Blackhall FH, et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30:172 - 178; PMID: 22124104; http://dx.doi.org/10.1200/JCO.2010.333.7089
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008; 99:2006 - 2012; PMID: 19078952; http://dx.doi.org/10.1038/sj.bjc.6604808
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1,800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009; 65:192 - 197; PMID: 19409645; http://dx.doi.org/10.1016/j.lungcan.2009.03.027
   PubMed Web of Science ®Google Scholar
• Antisoma plc. ATTRACT-1 phase III trial of ASA404 halted following interim analysis July 27, 2010 Press release. March 29, 2010. http://www.antisoma.com/asm/media/press/pr2010/2010-03-29/
   Google Scholar
• Antisoma plc. Antisoma announces outcome of ASA404 ATTRACT-2 trial November 24, 2010 Press release. November 11, 2010. http://www.antisoma.com/asm/media/press/pr2010/2010-11-11/
   Google Scholar
• Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2965 - 2971; PMID: 21709202; http://dx.doi.org/10.1200/JCO.2011.35.0660
   PubMed Web of Science ®Google Scholar
• Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2011; 29:1075 - 82; http://dx.doi.org/10.1200/JCO.2010.32.5944
   PubMed Web of Science ®Google Scholar
• Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, et al. NPI-2358 is a tubulindepolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006; 17:25 - 31; PMID: 16317287; http://dx.doi.org/10.1097/01.cad.0000182745.01612.8a
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Lee JJ, Blumenschein GRJ, Tsao A, Alden CM, et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer 101st Annual Meeting of the American Association for Cancer Research April 17–21, 2010 Washington DC
   Google Scholar
• Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-smallcell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28:949 - 954; PMID: 20085937; http://dx.doi.org/10.1200/JCO.2009.25.4482
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). [Abstract 3039]. J Clin Oncol 2010; 28
   Google Scholar
• Goodwin R, Ding K, Seymour L, LeMaître A, Arnold A, Shepherd FA, et al, NCIC Clinical Trials Group, Kingston, Ontario, Canada. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010; 21:2220 - 2226; PMID: 20427348; http://dx.doi.org/10.1093/annonc/mdq221
   PubMed Web of Science ®Google Scholar
• Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010; 70:2171 - 2179; PMID: 20215520; http://dx.doi.org/10.1158/0008-5472.CAN-09-2533
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials.gov/.
   Google Scholar